Sanofi still has the right to select up to two drugs per year for partnership. If they select a drug, they must pay IDM an upfront fee and also pay for all development cost. Sanofi has this right for atleast a few more years. They dropped Uvidem in Jan and they also gave up their right of first refusal on Uvidem. So in other words, Uvidem is completely under the control of IDM, which in the long-run is a good thing because Uvidem was stagnant under Sanofi.
Of course the long-run is highly dependent on Mepact/Mtp getting approved in Europe and then the US. The EMEA just inspected the COG and IDM is getting the CMC questions answered by the June meeting so things are looking positive on the Mepact front.
IDM has all marketing rights to MTP but they will have to pay Novartis 2.75 million if MTP becomes profitable.
My research shows that Sanofi and Medarex still own their IDM shares. IDM had a deal to use some of Medarex's proprietary technology/biology but I don't think they still use/need this.
Page 25 of the April 28 SEC filing shows the stock ownership numbers of the large holders as well as the oficers and directors. Palo Alto has the largest stake with about 7.3 million shares.
News 
Market Data 
Discover 
AI
